139 related articles for article (PubMed ID: 37259357)
1. Design, Synthesis and Phenotypic Profiling of Simplified Gedatolisib Analogues.
Costa CMX; Aparecida-Silva C; Gamba LER; de Melo TN; Barbosa G; Moraes Junior MO; de Oliveira VRT; de Amorim CS; Moraes JA; Barreiro EJ; Lima LM
Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259357
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells.
Murase Y; Hosoya K; Sato T; Kim S; Okumura M
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35088890
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic and Antiproliferative Activity of LASSBio-2208 and the Attempts to Determine Its Drug Metabolism and Pharmacokinetics In Vitro Profile.
Pillpe-Meza RM; Gouveia WL; Barbosa G; Fraga CAM; Barreiro EJ; Lima LM
Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543175
[TBL] [Abstract][Full Text] [Related]
4. Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models.
Rossetti S; Broege A; Sen A; Khan S; MacNeil I; Molden J; Kopher R; Schulz S; Laing L
NPJ Breast Cancer; 2024 Jun; 10(1):40. PubMed ID: 38839777
[TBL] [Abstract][Full Text] [Related]
5. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
6. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings.
Shor RE; Dai J; Lee SY; Pisarsky L; Matei I; Lucotti S; Lyden D; Bissell MJ; Ghajar CM
Mol Oncol; 2022 Jan; 16(1):130-147. PubMed ID: 34058066
[TBL] [Abstract][Full Text] [Related]
8. ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells.
Liu C; Xing W; Yu H; Zhang W; Si T
Cancer Cell Int; 2021 Feb; 21(1):108. PubMed ID: 33593355
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.
Del Campo JM; Birrer M; Davis C; Fujiwara K; Gollerkeri A; Gore M; Houk B; Lau S; Poveda A; González-Martín A; Muller C; Muro K; Pierce K; Suzuki M; Vermette J; Oza A
Gynecol Oncol; 2016 Jul; 142(1):62-69. PubMed ID: 27103175
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors.
Wu TT; Guo QQ; Chen ZL; Wang LL; Du Y; Chen R; Mao YH; Yang SG; Huang J; Wang JT; Wang L; Tang L; Zhang JQ
Eur J Med Chem; 2020 Oct; 204():112637. PubMed ID: 32717477
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Putative Dual Inhibitor of Tubulin and EGFR by Phenotypic Approach on LASSBio-1586 Homologs.
Barbosa G; Gelves LGV; Costa CMX; Franco LS; Lima JAL; Aparecida-Silva C; Teixeira JD; Mermelstein CDS; Barreiro EJ; Lima LM
Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 35893736
[TBL] [Abstract][Full Text] [Related]
12. Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents
Su Q; Xu B; Tian Z; Gong Z
Acta Pharm; 2022 Sep; 72(3):389-402. PubMed ID: 36651540
[TBL] [Abstract][Full Text] [Related]
13. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Wainberg ZA; Alsina M; Soares HP; Braña I; Britten CD; Del Conte G; Ezeh P; Houk B; Kern KA; Leong S; Pathan N; Pierce KJ; Siu LL; Vermette J; Tabernero J
Target Oncol; 2017 Dec; 12(6):775-785. PubMed ID: 29067643
[TBL] [Abstract][Full Text] [Related]
14. Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors.
Colombo I; Genta S; Martorana F; Guidi M; Frattini M; Samartzis EP; Brandt S; Gaggetta S; Moser L; Pascale M; Terrot T; Sessa C; Stathis A
Clin Cancer Res; 2021 Sep; 27(18):5012-5019. PubMed ID: 34266890
[TBL] [Abstract][Full Text] [Related]
15. Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion.
Houk BE; Alvey CW; Visswanathan R; Kirkovsky L; Matschke KT; Kimoto E; Ryder T; Obach RS; Durairaj C
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):22-31. PubMed ID: 30256541
[TBL] [Abstract][Full Text] [Related]
16. Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer.
Wilson GD; Wilson TG; Hanna A; Dabjan M; Buelow K; Torma J; Marples B; Galoforo S
Clin Transl Radiat Oncol; 2021 Jan; 26():15-23. PubMed ID: 33251343
[TBL] [Abstract][Full Text] [Related]
17. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Beale G; Haagensen EJ; Thomas HD; Wang LZ; Revill CH; Payne SL; Golding BT; Hardcastle IR; Newell DR; Griffin RJ; Cano C
Br J Cancer; 2016 Sep; 115(6):682-90. PubMed ID: 27529512
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
Makinoshima H; Umemura S; Suzuki A; Nakanishi H; Maruyama A; Udagawa H; Mimaki S; Matsumoto S; Niho S; Ishii G; Tsuboi M; Ochiai A; Esumi H; Sasaki T; Goto K; Tsuchihara K
Cancer Res; 2018 May; 78(9):2179-2190. PubMed ID: 29490947
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
[TBL] [Abstract][Full Text] [Related]
20. Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.
Radovich M; Solzak JP; Wang CJ; Hancock BA; Badve S; Althouse SK; Bray SM; Storniolo AMV; Ballinger TJ; Schneider BP; Miller KD
Clin Cancer Res; 2022 Aug; 28(15):3235-3241. PubMed ID: 35551360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
